Rebamipide
DRACPC ID DRACPC0090
Active Ingredients Rebamipide
Description A quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.
Synonyms alpha-[(4-Chlorobenzoyl)amino]-1,2-dihydro-2-oxo-4-quinolinepropanoic Acid; OPC 12759; Rebamipide
Type Small Molecule
Disease Early Gastric Cancer, Stomach Ulcer, Keratoconjunctivitis Sicca, Gastric Adenoma
Classification
Amino acid and derivative
Structure Information
Molecular Formula C19H15ClN2O4
Molecular Weight 370.8
Active Sequence Not available
Sequence Length Not available
Modification Not available
IUPAC Name 2-[(4-chlorophenyl)formamido]-3-(2-oxo-1,2-dihydroquinolin-4-yl)propanoic acid
InChI InChI=1S/C19H15ClN2O4/c20-13-7-5-11(6-8-13)18(24)22-16(19(25)26)9-12-10-17(23)21-15-4-2-1-3-14(12)15/h1-8,10,16H,9H2,(H,21,23)(H,22,24)(H,25,26)
InChI_Key ALLWOAVDORUJLA-UHFFFAOYSA-N
SMILES O=C(O)C(NC(C1=CC=C(Cl)C=C1)=O)CC2=CC(NC3=C2C=CC=C3)=O
External Codes
PubChem CID 5042
DrugBank Accession Number DB11656
NCI Thesaurus Code C29852
UNII LR583V32ZR GSRS
CAS 90098-04-7
Drug approval
Drug indication
Rebamipide has been investigated for the treatment of Stomach Ulcer, Keratoconjunctivitis Sicca, and Gastric Adenoma and Early Gastric Cancer.
The drug is not approved.
| ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
|---|---|---|---|---|
| NCT02085460 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 2 Trial of Rebamipide Liquid to Determine the Effective Dose for Prevention of Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer | Head and Neck Cancer | Phase 2 | Treatment |
| NCT02243618 | The Effect of Proton Pump Inhibitor and Polaprezinc Combination Therapy for Healing of Endoscopic Submucosal Dissection-induced Ulcer | Gastric Adenoma; Early Gastric Cancer | Not Applicable | Treatment |
| NCT03608761 | Comparison Between Rebamipide 2% Versus Autologous Serum in the Treatement of the Moderate to Severe Dry Eye Associate With Sjögren Syndrome. Pilot, Crossed, Controled, Randomized And Open Study | Dry Eye Syndromes; Sjögren Syndrome | Phase 4 | Treatment |
More clinical information is obtained from ClinicalTrials.gov.
